# Xenograft and organoid model systems in cancer research

Review · Bleijs M, van de Wetering M, Clevers H, Drost J

- Archive id: doi:10.15252/embj.2019101654
- Published: 2019-07-08
- Venue: The EMBO journal
- DOI: https://doi.org/10.15252/embj.2019101654
- PMID: 31282586
- PMCID: PMC6670015
- Citations: 338
- Source URL: https://doi.org/10.15252/embj.2019101654
- PDF: https://europepmc.org/articles/PMC6670015/pdf
- Provenance: europepmc

## Abstract

Patient-derived tumour xenografts and tumour organoids have become important preclinical model systems for cancer research. Both models maintain key features from their parental tumours, such as genetic and phenotypic heterogeneity, which allows them to be used for a wide spectrum of applications. In contrast to patient-derived xenografts, organoids can be established and expanded with high efficiency from primary patient material. On the other hand, xenografts retain tumour-stroma interactions, which are known to contribute to tumorigenesis. In this review, we discuss recent advances in patient-derived tumour xenograft and tumour organoid model systems and compare their promises and challenges as preclinical models in cancer research.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [Organoids & Organ-on-Chip](https://space-kitty.com/topics/organoids)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.